Genmab A/S (NASDAQ:GMAB) Shares Gap Down – Time to Sell?

Genmab A/S (NASDAQ:GMAB) gapped down before the market opened on Tuesday . The stock had previously closed at $19.58, but opened at $19.09. Genmab A/S shares last traded at $18.95, with a volume of 227,258 shares traded.

Wall Street Analyst Weigh In

GMAB has been the subject of a number of research analyst reports. Leerink Partnrs raised Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Sanford C. Bernstein downgraded Genmab A/S from a “market perform” rating to an “underperform” rating in a research note on Tuesday. BNP Paribas raised shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research report on Tuesday, February 11th. Leerink Partners raised shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 price target on the stock in a research report on Thursday, February 13th. Finally, William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a research note on Tuesday, March 11th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, eight have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $41.33.

Genmab A/S Stock Up 0.9 %

The company’s 50 day moving average is $20.76 and its 200 day moving average is $21.71. The firm has a market capitalization of $12.45 billion, a price-to-earnings ratio of 10.82, a P/E/G ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last announced its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%. On average, analysts expect that Genmab A/S will post 1.45 EPS for the current year.

Institutional Investors Weigh In On Genmab A/S

Institutional investors and hedge funds have recently bought and sold shares of the company. EverSource Wealth Advisors LLC raised its position in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock valued at $26,000 after buying an additional 939 shares in the last quarter. Lindbrook Capital LLC increased its stake in Genmab A/S by 105.4% in the fourth quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock valued at $39,000 after acquiring an additional 950 shares during the last quarter. GAMMA Investing LLC raised its position in Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after purchasing an additional 1,051 shares in the last quarter. Barclays PLC lifted its stake in Genmab A/S by 1,072.8% during the fourth quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after purchasing an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC boosted its holdings in shares of Genmab A/S by 656.8% in the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock valued at $60,000 after purchasing an additional 2,496 shares in the last quarter. Institutional investors own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.